Cargando…

Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection

A 49-year-old man underwent treatment with glecaprevir plus pibrentasvir (G/P) for chronic hepatitis C infection. Six weeks later, he was admitted to our hospital because of jaundice and fatigue with no accompanying skin rash. A laboratory examination and evaluation of the patient’s history resulted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hara, Tasuku, Ohara, Tomoya, Taniguchi, Masashi, Sakai, Hiroaki, Oka, Kohei, Iwai, Naoto, Tsuji, Toshifumi, Okuda, Takashi, Nagata, Akihiro, Komaki, Toshiyuki, Sakagami, Junichi, Kagawa, Keizo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381168/ https://www.ncbi.nlm.nih.gov/pubmed/33612683 http://dx.doi.org/10.2169/internalmedicine.6664-20

Ejemplares similares

Development of Hepatocellular Carcinoma in a Patient with Chronic Hepatitis C 21 Years after Achieving a Sustained Virological Response to Interferon Therapy
por: Hara, Tasuku, et al.
Publicado: (2020)

Unusual abscess formation in colon cancer with mucinous components
por: Iwai, Naoto, et al.
Publicado: (2021)

Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer
por: Iwai, Naoto, et al.
Publicado: (2020)

Red dichromatic imaging improves visibility of bleeding during gastric endoscopic submucosal dissection
por: Oka, Kohei, et al.
Publicado: (2023)

Depletion of Psoas Muscle Mass after Systemic Chemotherapy Is Associated with Poor Prognosis in Patients with Unresectable Pancreatic Cancer
por: Iwai, Naoto, et al.
Publicado: (2021)

Interstitial Lung Disease Associated with Agaricus blazei Murill in a Patient with Pancreatic Ductal Adenocarcinoma Receiving Gemcitabine-Based Therapy
por: Iwai, Naoto, et al.
Publicado: (2022)

Clinical Features of False-Negative Early Gastric Cancers: A Retrospective Study of Endoscopic Submucosal Dissection Cases
por: Oka, Kohei, et al.
Publicado: (2021)

Hepatitis B Virus Reactivation 55 Months Following Chemotherapy Including Rituximab and Autologous Peripheral Blood Stem Cell Transplantation for Malignant Lymphoma
por: Hara, Tasuku, et al.
Publicado: (2020)

Over‐the‐scope clip closure of gastric endoscopic submucosal dissection‐induced ulcer in a patient with bleeding tendency
por: Iwai, Naoto, et al.
Publicado: (2022)

Tiny capillary hemangioma of the ileum as the cause of chronic anemia
por: Iwai, Naoto, et al.
Publicado: (2020)

Cervical squamous cell carcinoma coexisting with ectopic gastric mucosa treated by endoscopic submucosal dissection: A case report
por: Tsuji, Toshifumi, et al.
Publicado: (2020)

Laparoscopy Endoscopy Cooperative Surgery for Inflammatory Fibroid Polyp in the Esophagus
por: Oka, Kohei, et al.
Publicado: (2019)

Comparison of the effect of light alcohol consumption on Japanese men with and without fatty liver
por: Hara, Tasuku, et al.
Publicado: (2019)

Comparison of the effect of light alcohol consumption on Japanese men with and without fatty liver
por: Hara, Tasuku, et al.
Publicado: (2020)

Helicobacter pylori eradication increases the serum high density lipoprotein cholesterol level in the infected patients with chronic gastritis: A single-center observational study
por: Iwai, Naoto, et al.
Publicado: (2019)

Gastric Metastasis from Colorectal Cancer Mimicking a Submucosal Tumor
por: Iwai, Naoto, et al.
Publicado: (2020)

Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older
por: Komaki, Yuri, et al.
Publicado: (2022)

Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
por: Reau, Nancy, et al.
Publicado: (2023)

Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
por: Huang, Chung-Feng, et al.
Publicado: (2021)

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection
por: Liu, Xiaoqing, et al.
Publicado: (2021)

Endoscopic band ligation for a rectal Dieulafoy’s lesion
por: Iwai, Naoto, et al.
Publicado: (2020)

Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients with Chronic Hepatitis C Infection
por: Flamm, Steven L., et al.
Publicado: (2020)

Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
por: Lampertico, Pietro, et al.
Publicado: (2020)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019)

Risk Factors of Glecaprevir/Pibrentasvir-Induced Liver Injury and Efficacy of Ursodeoxycholic Acid
por: Tamai, Hideyuki, et al.
Publicado: (2023)

Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study
por: Cornberg, Markus, et al.
Publicado: (2022)

Anaplastic carcinoma of the pancreas diagnosed by endoscopic ultrasound-guided fine-needle aspiration: a case report and review of the literature
por: Oka, Kohei, et al.
Publicado: (2018)

Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
por: Akutsu, Noriyuki, et al.
Publicado: (2021)

Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
por: Reau, Nancy, et al.
Publicado: (2018)

Four Weeks Treatment with Glecaprevir/Pibrentasvir + Ribavirin—A Randomized Controlled Clinical Trial
por: Madsen, Lone W., et al.
Publicado: (2022)

Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension
por: Brown, Robert S., et al.
Publicado: (2022)

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment
por: Arora, Rishi, et al.
Publicado: (2023)

Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment
por: Yap, Desmond Y. H., et al.
Publicado: (2020)

Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis
por: Back, David, et al.
Publicado: (2019)

Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases
por: Sugiura, Ayumi, et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study
por: Jonas, Maureen M., et al.
Publicado: (2021)

High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence
por: Zamor, Philippe J., et al.
Publicado: (2021)

Efficacy of Glecaprevir/Pibrentasvir for Real-World HCV Infected Patients in the Northern Part of Tokyo, Japan
por: Yamana, Yoichiro, et al.
Publicado: (2021)

Acute Kidney Injury Presenting as Hepatorenal Syndrome in the Setting of Glecaprevir/Pibrentasvir Treatment for Hepatitis C
por: Fansiwala, Kush, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dfs1oi8cem4tduo41nop00eaag